



PRIOR AUTHORIZATION REQUEST FORM

MOUNJARO and GLP-1s

Bydureon®, Ozempic®, Rybelsus®, Trulicity®, and Victoza®

For authorization, please answer each question and fax this form PLUS chart notes back to Real Rx at 385-425-4052.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for assistance 385-425-5094.

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Form with fields: Date, Member Name, ID#, DOB, Gender, Physician, Office Phone, Office Fax, Office Contact.

Height/Weight:

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Preferred:

Bydureon® (exenatide), Ozempic® (semaglutide), Rybelsus®(semaglutide), Trulicity®(dulaglutide), and Victoza®(liraglutide), Mounjaro®(tirzapatide)

Dosing/Frequency:

If the request is for reauthorization, proceed to reauthorization section.

Table with 4 columns: Questions, Yes, No, Comments/Notes. Contains 3 rows of questions regarding expedited review, diabetes diagnosis, and generic medication trials.

REAUTHORIZATION

Table with 4 columns: Questions, Yes, No, Comments/Notes. Contains 3 rows of reauthorization questions regarding therapy request, medical need, and therapy tolerability.

What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.

Additional information:

Physician Signature:

**\*\* Failure to submit clinical documentation to support this request will result in a dismissal of the request.\*\***

Policy: PHARM- 148  
Origination Date: 01/11/2023  
Reviewed/Revised Date: 01/18/2023  
Next Review Date: 01/18/2024  
Current Effective Date: 02/01/2023

**Confidentiality Notice**

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.